Document is current
Any future updates will be listed below
-
Authors
Pernice, Helena F. https://orcid.org/0009-0001-8711-5526
Knorz, Adrian L. https://orcid.org/0000-0002-7924-0394
Wetzel, Paul J. https://orcid.org/0009-0001-9393-5512
Herrmann, Carolin https://orcid.org/0000-0003-2384-7303
Muratovic, Harisa
Rieber, Finn https://orcid.org/0009-0004-7833-2272
Asaad, Eleonora https://orcid.org/0009-0002-2677-3266
Fiß, Gunnar
Barzen, Gina https://orcid.org/0000-0002-1329-2159
Blüthner, Elisabeth https://orcid.org/0000-0002-7008-8795
Knebel, Fabian https://orcid.org/0000-0002-2095-6806
Spethmann, Sebastian https://orcid.org/0000-0003-0987-8007
Messroghli, Daniel
Heidecker, Bettina https://orcid.org/0000-0002-3811-7920
Brand, Anna
Wetz, Christoph https://orcid.org/0000-0002-7392-1375
Tschöpe, Carsten https://orcid.org/0000-0001-5243-8985
Hahn, Katrin https://orcid.org/0000-0002-6013-0072
-
Funding
Funding for this research was provided by:
Alnylam pharmaceutics
Deutsche Gesellschaft für Muskelkranke
Takeda Pharmaceuticals Inc.
Pfizer
Foundation Charité
Boehringer Ingelheim
AstraZeneca
Novartis
Charité - Universitätsmedizin Berlin
- License Information
-
More Information
Article History
Received: 5 January 2024
Accepted: 17 April 2024
First Online: 2 May 2024
Competing interests
: Helena Pernice has received personal funding, travel support, and speaker fees by Alnylam Pharmaceuticals Inc. HP also received personal funding by Deutsche Gesellschaft für Muskelkranke (DGM) GmbH. Adrian Knorz, Gunnar Fiß, Harisa Muratovic, Paul Wetzel, Finn Rieber, Carolin Herrmann and Eleonora Asaad declare they have no conflict of interest. Katrin Hahn received financial reimbursement for consulting, advisory board activities, speaker fees and/or contributions to congresses and travel support to attend scientific meetings by Akcea Therapeuticals Inc., Alnylam Pharmaceuticals Inc., Amicus, AstraZeneca, GSK, Hormosan, Takeda Pharmaceutical Inc., Pfizer Pharmaceuticals Inc., Swedish Orphan Biovitrum Inc and ViiV Healthcare GmbH. KH further received research funding by the foundation Charité (BIH clinical fellow), Alnylam Pharmaceuticals Inc., and Pfizer Pharmaceuticals. Fabian Knebel received speaker honoraria from Alnylam Inc., Pfizer Inc., and research support from Alnylam Inc and Pfizer Inc. Christoph Wetz received a speaker honorarium from Company Novartis, Pfizer and Alnylam Pharmaceuticals; and received grants/research support from Novartis. Bettina Heidecker has received speaker fees and research funding from Pfizer Pharmaceuticals Inc., AstraZeneca, and Boehringer Ingelheim unrelated to this project. Fabian Knebel received speaker honoraria from Alnylam Inc., Pfizer Inc., and research support from Alnylam Inc and Pfizer Inc. Sebastian Spethmann received financial reimbursement for lectures from Pfizer Pharmaceuticals. Elisabeth Blüthner received consultation, lecture, advisory board honoraria and grant research support from Takeda Pharmaceuticals Inc. Anna Brand received a speaker honorarium from Pfizer. Daniel Messroghli has received honoraria for speaking at symposia from Pfizer, Alnylam and Akcea and research funding from Pfizer. Carsten Tschöpe has received speaker fees and/or contributions to congresses from Abbott, Abiomed, Astra Zeneca, Bayer, Novartis, Pfizer, and Servier; all outside the submitted work. Gina Barzen received personal funding by Alnylam Pharmaceuticals Inc.
